Systemic antiviral drugs used in ophthalmology

Survey of Ophthalmology

Volumn 37, Issue 1, 1992, Pages 19-53

  Teich, Steven A ^a   Cheung, Tony W ^a   Friedman, Alan H ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

acquired immune deficiency syndrome; acute retinal necrosis; antiviral drugs; conjunctivitis; cytomegalovirus; herpes viruses; HIV; keratitis; retinitis; uveitis

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; DIDANOSINE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; INTERFERON; VIDARABINE; VIRUS PROTEIN; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; CONJUNCTIVITIS; CYTOMEGALOVIRUS INFECTION; DIGESTIVE SYSTEM FUNCTION DISORDER; HERPES VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA; KERATITIS; KIDNEY DISEASE; KIRISAWA UVEITIS; NEUTROPENIA; OPHTHALMOLOGY; PANCREATITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RETINITIS; REVIEW; THROMBOCYTOPENIA; UREMIA; UVEITIS; VIRUS INFECTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ACYCLOVIR; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; EYE INFECTIONS, VIRAL; FOSCARNET; GANCICLOVIR; HUMAN; INTERFERON ALFA-2B; KERATITIS, HERPETIC; PHOSPHONOACETIC ACID; SUPPORT, NON-U.S. GOV'T; VIDARABINE; ZIDOVUDINE;

EID: 0026633066     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/0039-6257(92)90003-C     Document Type: Review

References (483)

1. Expanding ophthalmic recognition of Epstein-Barr virus infections
2. Intravenous adenine arabinoside against herpes simplex keratouveitis in humans
3. Treatment of CMV retinitis in an AIDS patient
4. Management of Epstein-Barr virus infections
5. Platelet function in bilateral acute retinal necrosis
6. Drugs that cause psychiatric symptoms
7. Foscarnet for cytomegalovirus pneumonitis (Letter)
8. Human leukocyte interferon for the treatment of varicella in children with cancer
9. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis
10. Preclinical toxicity of zidovudine: An overview
11. 9-(1,3-dihydroxy-2-propoxymethyl) guanine for cytomegalovirus infections in patients with the acquired immunodeficiency syndrome
12. Resistance of herpes simplex to acyclovir
13. Acyclovir therapy for herpes zoster: Advantages and adverse effects
14. Acyclovir
15. Varicella zoster virus infections in immunocompromised hosts: a review of the natural history and management
16. Acyclovir halts progression of herpes zoster in immunocompromised patients
17. A randomized placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts
18. Antiviral drugs in pediatrics
19. Acyclovir in immunocompromised patients with cytomegalovirus disease
20. Intravenous acyclovir therapy for varicella in immunocompromised children
21. Acyclovir treatment of varicella in otherwise healthy children
22. The interferons: mechanisms of action and clinical applications
23. Acyclovir therapy for acute herpes zoster
24. Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster
25. Declining levels of HIV p24 antigen in serum during treatment with foscarnet
26. Hypertrichosis of the eyelashes associated with interferonalpha therapy for chronic granulocytic leukemia
27. Oral acyclovir reduces the incidence of recurrent herpes simplex keratitis in rabbits after penetrating keratoplasty
28. Antivirals and interferons
29. Systemische Acyclovir Therapie bei Rezidivierender durch Herpes Simplex Virus bedingter Keratouveitis
30. In vitro susceptibility of varicellazoster virus to acyclovir
31. The diagnosis of cytomegalovirus retinitis
32. Treatment of the acute retinal necrosis syndrome with intravenous acyclovir
33. Clinical and biological effects of recombinant interferon-beta administered intravenously daily in phase I trial
34. Renal function after acyclovir intravenous injection
35. Association of varicella zoster dermatitis with acute retinal necrosis syndrome
36. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir: A randomized double-blind controlled trial in normal subjects
37. Plasma levels and urinary excretion of vidarabine after repeated dosing
38. Vidarabine (Vira A) pharmacology and clinical experience
39. Can AZT treatment in AIDS patients aggravate pre-existing CMV retinitis
40. Longterm intravitreal ganciclovir for cytomegalovirus retinitis in a patients with AIDS
41. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus
42. Zona ophtalmique aigu traite par acyclovir oral: Resultats preliminairies
43. Ganciclovir: Clinical pharmacokinetics, safety and antiviral activity
44. Ganciclovir treatment of life-or-sight-threatening cytomegalovirus infection: Experience in 314 immunocompromised patients
45. Recovery of human immunodeficiency virus from ocular tissues in patients with acquired immune deficiency syndrome
46. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir: Long-term results
47. Acute retinal necrosis
48. Clinical, immunological, and virological effects of ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex
49. Hypertrichosis of the eyelashes in acquired immunodeficiency syndrome
50. Concomitant ganciclovir and zidovudine treatment for cytomegalovirus retinitis in patients with HIV infection: An approach to treatment
51. Public Health Service statement on management of occupational exposure to human immunodeficiency virus, including considerations regarding zidovudine post-exposure use
52. Safety of therapeutic immune globulin preparations with respect to transmission of human T-lymphotropic virus type III/lymphadenopathy associated virus infection
53. 9-(13-dihydroxy-2-propoxymethyl) guanine (ganciclovir) in the treatment of cytomegalovirus gastrointestinal disease with the acquired immunodeficiency syndrome
54. Ocular herpes simplex virus infections: Reduced sensitivity to acyclovir in primary disease
55. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome
56. Zoster-related bilateral acute retinal necrosis syndrome as presenting sign in AIDS
57. Effect of adenine arabinoside on cytomegalovirus infection
58. Apha-interferon administration in cytomegalovirus retinitis
59. Preclinical toxicology studies with acyclovir genetic toxicity tests
60. Reduction of the ocular complications of herpes zoster ophthalmicus by oral acyclovir
61. Oral acyclovir in the therapy of acute herpes zoster ophthalmicus: an interim report
62. Oral acyclovir to the treatment of acute herpes zoster ophthalmicus
63. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome
64. Severe but reversible neurotoxicity from acyclovir
65. Antiviral activity of 2′-deoxy-2′-fluoro-beta-D-arabinofuranosyl-5-iodocytosine against human cytomegalovirus in human skin fibroblast
66. Effect of acyclovir [9-(2-hydroxyethoxymethyl) guanine] on Epstein-Barr virus DNA replication
67. Herpes zoster ophthalmicus and acquired immunodeficiency syndrome
68. Varicella-zoster virus does not become resistant to acyclovir during therapy
69. In vitro susceptibility of cytomegalovirus isolates from immunosuppressed patients to acyclovir and ganciclovir
70. Combination therapy for dendritic keratitis with human leukocyte inferferon and acyclovir
71. Acyclovir in herpetic anterior uveitis
72. Treatment of serious cytomegalovirus infections with 9-(13-dihydroxy-2-propoxymethyl) guanine in patients with AIDS and other immunodeficiencies
73. Oral acyclovir in herpetic keratitis
74. Acyclovir (Zovirax) in herpetic disciform keratitis
75. Oral acyclovir (Zovirax) in herpes simplex dendritic corneal ulceration
76. Interferon nomenclature
77. Prevention of cytomegalovirus infection by prophylaxis with an intravenous hyperimmune, native, unmodified cytomegalovirus globulin
78. Once-daily administration of 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex: Results of a phase I trial
79. Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: Results of topical, intravenous, and oral therapy
80. Prompt treatment of early acute retinal necrosis: A more favorable prognosis [abstract]
81. Echovirus polymyositis in patients with hypogamma-globulinemia. Failure of high dose intravenous gamma-globulin therapy and review of the literature
82. Molecular targets of antiviral therapy
83. Growth inhibition by acycloguanosine of herpes viruses isolated from human infections
84. Varicella zoster virus is a cause of the acute retinal necrosis syndrome
85. The acute retinal necrosis syndrome: Part II. Histopathology and etiology
86. Intravenous and intraocular ganciclovir for CMV retinitis in patients with AIDS or chemotherapeutic immunosuppression
87. Mitochondrial myopathy caused by long-term zidovudine therapy
88. Resolution of cytomegalovirus retinitis with zidovudine therapy
89. Ophthalmoscopic and histologic findings in cytomegalovirus retinitis treated with BW-B759U
90. Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance
91. Central nervous system side effects of ganciclovir
92. Treatment of chronic hepatitis C with recombinant interferon alfa: A multicenter randomized controlled trial
93. Interferon in viral hepatitis: Role in pathogenesis and treatment
94. Immediate-early gene region of human cytomegalovirus trans-activates the promoter of human immunodeficiency virus
95. The Herpetic Eye Disease Study
96. Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus
97. Combination therapy for dendritic keratitis with acyclovir and alpha-interferon
98. Combination therapy for dendritic keratitis with human leucocyte interferon and trifluorothymidine
99. Effects of acyclovir therapy during simultaneous reactivation of latent HSV-1 in rabbits
100. Acyclovir kinetics after intravenous infusion
101. Ocular manifestations in pediatric patients with acquired immunodeficiency syndrome
102. Prevention of foscarnet nephrotoxicity
103. Toxicity of intravitreally administered alpha-interferon
104. Recombinant interferon alfa therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial
105. Drugs five years later: Acyclovir
106. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection
107. Cytomegalovirus infection in patients with AIDS
108. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection
109. Diagnosis and management of the acute retinal necrosis (ARN) syndrome
110. Rapidly progressive outer retinal necrosis in the acquired immunodeficiency syndrome
111. A controlled trial of acyclovir for chickenpox in normal children
112. Acute renal failure and coma after a high dose of oral acyclovir
113. Cytomegalovirus retinitis in immunosuppressed hosts II Ocular manifestations
114. Combination of ganciclovir and beta-interferon for prevention of relapse of AIDS-associated cytomegalovirus retinitis: Preliminary report [abstract]
115. Mechanism of action and selectivity of acyclovir
116. Selectivity of action of an antiherpetic agent 9-(2-hydroxyethoxymethyl) guanine
117. Cytomegalovirus pneumonia after bone-marrow transplantation successfully treated with the combination of ganciclovir and high dose intravenous immune globulin
118. Treatment of resistant herpes simplex virus with continuous-infusion acyclovir
119. Herpes simplex virus resistant to acyclovir: A study in a tertiary care center
120. Chronic herpes zoster virus keratitis associated with the acquired immunodeficiency syndrome
121. Potent synergistic inhibition of herpes simplex virus-2 by 9-[(1,3 dehydroxy-2-propoxy)methyl] guanine in combination with recombinant interferons
122. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients
123. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts
124. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome
125. Prednisolone does not prevent post-herpetic neuralgia
126. Rational acyclovir therapy in herpetic eye disease
127. Ganciclovir — A review of pharmacology, therapeutic efficacy and potential use for treatment of congenital cytomegalovirus infections
128. Foscarnet therapy of cytomegalovirus retinitis in AIDS
129. Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis
130. Response of human immunodeficiency virus-associated uveitis to zidovudine
131. Phosphonoformate (foscarnet): A pilot study in AIDS and AIDS related complex
132. Atypical retinitis in patients with the acquired immunodeficiency syndrome
133. Treatment of adult chickenpox with oral acyclovir
134. Varicella in children with cancer: Impact of antiviral therapy and prophylaxis
135. Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine
136. Susceptibility of herpes viruses to three nucleoside analogues and their combinations and enhancement of the antiviral effect at acid pH
137. Response to neurologic complications of AIDS to 3′-azido-3′-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl) guanine. I. Clinical features
138. Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo
139. New facets of zidovudine therapy
140. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double blind, placebo-controlled trial
141. The safety and efficacy of zidovudine (AZT) in the treatment of patients with mildly symptomatic HIV infection A double-blind placebo-controlled trial
142. Continuous infusion of high dose acyclovir for serious herpes virus infections
143. Pharmacokinetics and safety of high dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation
144. Phase 1 study of the safety and pharmacokinetics of oral ganciclovir [abstract]
145. Increased growth of eyelashes in a patient given leukocyte interferon
146. Rapidly progressive outer retinal necrosis in the acquired immunodeficiency syndrome
147. GM-CSF and ganciclovir for cytomegalovirus infection after autologous bone-marrow transplantation
148. 2-fluoro-arabinosyl pyrimidine nucleosides: Chemistry, antiviral, and potential anticancer activities
149. Amantadine and corneal deposits
150. Demonstration of herpes group virus in acute retinal necrosis syndrome
151. Prevalence of AIDS-related retinal microvasculopathy
152. Prevalence, pathophysiology, and treatment of rhegmatogenous retinal detachment in treated cytomegalovirus retinitis
153. Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo
154. Adenine arabinoside and allopurinol: Possible adverse drug reaction
155. Viral origin of hairy leukoplakia
156. Herpes zoster. A possible clinical sign for development of acquired immunodeficiency syndrome in high-risk individuals
157. Inhibition of herpes simplex virus induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl) guanine and its triphosphate
158. Phosphorylation of 3′-azido-3′deoxythymidine and selective interaction of the 5′triphosphate with HIV reverse transcriptase
159. A controlled trial of recombinant human interferon gamma to prevent infection in chronic granulomatous disease
160. The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets, and lymphocyte function in AIDS patients
161. Genital and oral erosions induced by foscarnet
162. Ocular flutter in vidarabine toxicity
163. Treatment of infections associated with human immunodeficiency virus
164. Acyclovir prophylaxis for herpes simplex virus infection
165. Pulmonary and neurologic complications of treatment with FIAC (2′fluoro-5-iodo-aracytosine) in patients with acquired immune deficiency syndrome (AIDS)
166. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogenic bone marrow transplantation
167. Quantitation of herpes simplex virus type I shed in pre-ocular tear film of rabbits treated with acyclovir
168. Human interferon in viral diseases
169. Efficacy of desciclovir in the treatment of Epstein-Barr virus infection in oral hairy leukoplakia
170. Transplacental passage of acyclovir
171. Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome
172. Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome
173. Severe visual loss related to isolated peripapillary retinal and optic nerve head cytomegalovirus infection
174. GM-CSF with ganciclovir for the treatment of CMV retinitis in AIDS
175. Herpes simplex chorioretinitis in a healthy adult
176. Ganciclovir treatment of cytomegalovirus disease in immunocompromised children
177. Regression of cytomegalovirus retinitis with zidovudine: A clinicopathologic correlation
178. Natural history of herpes zoster ophthalmicus Predictors of postherpetic neuralgia and ocular involvement
179. Oral acyclovir in herpes zoster ophthalmicus
180. Combined ganciclovir and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients
181. Intravitreal ganciclovir in CMV retinitis: case report
182. Treatment of recurrent respiratory papillomatosis with human leukocyte interferon
183. Ganciclovir for treatment of renal transplant-associated primary cytomegalovirus pneumonia
184. High dose intravitreal gancyclovir for cytomegaloviral (CMV) retinitis
185. Staphylococcus epidermidis endophthalmitis complicating intravitreal antiviral therapy of cytomegalovirus retinitis
186. Longterm intravitreal ganciclovir therapy for cytomegalovirus retinopathy
187. Cytomegalovirus retinitis and response to therapy with ganciclovir
188. Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-1) associated with clinical exposures. A prospective evaluation
189. Prophylactic zidovudine after occupational exposure to the human immunodeficiency virus: An interim analysis
190. Use of intravitreal ganciclovir for CMV retinitis in a patient with AIDS
191. High dose oral acyclovir in acute herpes zoster ophthalmicus: The end of the corticosteroid era
192. Resistance to antiviral drugs: The end of innocence
193. Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal transplant recipients
194. Successful management of acute retinal necrosis with intravenous acyclovir
195. Ampligen for treatment of HIV infection: Clinical and laboratory findings of acute reactions
196. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS: An AIDS Clinical Trials Group Study
197. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy Use of a standardized system for the assessment of disease outcome
198. Acquired immune deficiency syndrome: Ocular manifestations
199. Treatment of cytomegalovirus retinopathy in patients with acquired immunodeficiency syndrome. Use of the experimental drug 9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine
200. Treatment of cytomegalovirus retinopathy with ganciclovir
201. Survival of patients with the acquired immune deficiency syndrome after development of cytomegalovirus retinopathy
202. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon
203. Therapy of herpes zoster with oral acyclovir
204. Oral acyclovir in the management of dendritic herpetic corneal ulceration
205. Pharmacokinetics of oral acyclovir (Zovirax) in the eye
206. The clinical use of human leukocyte interferon in viral infections
207. Cytomegalovirus retinitis and acquired immunodeficiency syndrome
208. Treatment of cytomegalovirus retinitis with ganciclovir
209. Presumed varicella zoster retinitis in immunocompromised patients
210. BW B759U for cytomegalovirus retinitis intraocular drug penetration
211. Ganciclovir therapy for opportunistic cytomegalovirus disease in AIDS
212. Acyclovirresistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with acquired immunodeficiency syndrome (AIDS)
213. Dose ranging study of daily intravenous maintenance foscarnet therapy for cytomegalovirus retinitis in AIDS patients (ACTG Protocol 015/915)[Abstract]
214. Effect of foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS
215. Human pharmacokinetics and tolerance of oral ganciclovir
216. Prolonged pancytopenia due to combined ganciclovir and zidovudine therapy
217. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS
218. Foscarnet-induced hypocalcemia and effect of foscarnet on calcium metabolism
219. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS)
220. Randomized, prospective trial of ganciclovir maintenance therapy for cytomegalovirus retinitis
221. Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome
222. Retinal and gastrointestinal disease due to cytomegalovirus in patients with acquired immune deficiency syndrome: Prevalence, natural history, and response to ganciclovir therapy
223. Failure of adjunctive cytomegalovirus intravenous immune globulin to improve efficacy of ganciclovir in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis: A phase 1 study
224. In vivo additive antiretroviral effect of combined zidovudine and foscarnet therapy for human immunodeficiency virus infection (ACTG Protocol 053)
225. Topical therapy of ulcerative herpetic keratitis with human interferon
226. Retinal toxicity of ganciclovir in vitrectomy infusion solution
227. Dermatologic findings and manifestations of acquired immunodeficiency syndrome (AIDS)
228. Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection
229. The use of 5-iodo-2′-deoxyuridine (IDU) in the treatment of herpes simplex keratitis
230. Ganciclovir treatment of cytomegalovirus infection in iatrogenically immunocompromised patients
231. Do corticosteroids prevent post-herpetic neuralgia?
232. Acyclovir tolerance in humans
233. Chickenpox chorioretinitis
234. Severe herpes zoster ophthalmicus in young African adults: a marker for HTLV-III seropositivity
235. Interferon and genital warts: Much potential, modest progress
236. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′deoxythymidine: A novel pyrimidine analog with potential application for the treatment of patients with AIDS and related disease
237. Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients
238. Effect of acyclovir on mammalian embryonic development in culture
239. Excessive growth of eyelashes in a patient with AIDS being treated with zidovudine
240. Treatment of disseminated cytomegalovirus infection with 9-(1,3 dihydroxy-2-propoxymethyl) guanine: Evidence of prolonged survival with the acquired immunodeficiency syndrome
241. Body mass repletion during ganciclovir treatment of cytomegalovirus infections in patients with acquired immunodeficiency syndrome
242. Combined zidovudine and interferon-alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS)
243. 6-Deoxyacyclovir: A xanthine oxidase-activated prodrug of acyclovir
244. Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS)
245. Suppression of recurrent genital herpes simplex virus infection with recombinant alfa 2 interferon
246. Optic neuritis associated with dideoxyinosine
247. Multicenter trial of acyclovir and trifluorothymidine in herpetic keratitis
248. Acyclovir and trifluorothymidine in herpetic keratitis—a multicentre trial
249. Zidovudine-induced macular edema
250. 2′3′-dideoxyinosine (ddI) in patients with acquired immunodeficiency syndrome or AIDS-related complex: A phase I trial
251. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection: A randomized, placebo controlled trial
252. Failure of Zidovudine prophylaxis after accidental exposure to HIV-1
253. Susceptibility to other antiherpes drugs of pathogenic variants of herpes simplex virus selected for resistance to acyclovir
254. Acyclovir. Pharmacology and clinical experience
255. Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus
256. Use of ganciclovir to treat serious cytomegalovirus infections in patients with AIDS
257. Interferon-alpha therapy of recurrent conjunctival papillomas
258. Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome
259. Herpes simplex virus type 1: A cause of the acute retinal necrosis syndrome
260. 2′-fluoro-5-iodoarabinosylcytosine, a new potent antiviral agent: Efficacy in immunosuppressed individuals with herpes zoster
261. Diagnosis and therapy of herpes zoster ophthalmicus
262. Acyclovir prophylaxis in bone-marrow transplant recipients
263. Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: Rationale for empiric dosing and plasma level monitoring
264. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro
265. Exogenous lactase in the treatment of oral acyclovir intolerance
266. Effect of 9-(1,3 dihydroxy-2-propoxymethyl) guanine on human cytomegalovirus replication in vivo
267. inhibition of cellular DNA polymerase alpha and human cytomegalovirus-induced DNA polymerase by the triphosphate of 9-(2-hydroxyethoxymethyl) guanine and 9-(1,3-dihydroxy-2-propoxymethyl) guanine
268. Effects of certain nucleoside analogues on human cytomegalovirus replication in vitro
269. Treatment of ocular disease in eczema herpeticum
270. Varicella-zoster virus retinitis in patients with the acquired immunodeficiency syndrome
271. A trial of vidarabine for cytomegalovirus infection in renal transplant patients
272. Mucocutaneous dissemination of acyclovir-resistant herpes simplex virus in a patient with AIDS
273. Effect of 9(1,3 dihydroxy-2-propoxymethyl) guanine on serious cytomegalovirus disease in eight immunosuppressed homosexual men
274. Ocular disease associated with Epstein-Barr virus infection
275. Epstein-Barr viral stromal keratitis
276. Acute retial necrosis as a novel complication of chickenpox in adults
277. A proposed mild type of acute retinal necrosis syndrome
278. Antiviral activity and mechanism of action of gancilovir
279. Oral acyclovir in herpes zoster
280. Oral acyclovir for herpes zoster
281. Oral acyclovir in acute herpes zoster
282. Interferon treatment of herpetic keratitis in a patient with acquired immunodeficiency syndrome
283. Antiviral drug sensitivity in ocular herpes simplex virus infection
284. Human leukocyte interferon for the treatment of herpes zoster in patients with cancer
285. Circulating p24 antigen levels and responses to dideoxycytidine to human immunodeficiency virus (HIV) infections
286. Diagnosis and treatment of genital herpes infection
287. Prolonged continuous versus intermittent oral acyclovir treatment in normal adults with frequently recurring genital herpes simplex virus infection
288. Longterm acyclovir suppression of frequently recurring genital herpes simplex virus infection
289. Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation
290. Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation
291. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation
292. Beta-interferon therapy in patients with poor prognosis Kaposi's sarcoma related to the acquired immunodeficiency syndrome (AIDS): A phase II trial with preliminary evidence of antiviral activity and low incidence of opportunistic infections
293. Antiviral activity of 9-B-D arabinofuranasyladenine. Cell culture studies
294. Intravenous acyclovir treatment for primary genital herpes
295. Long-term inhibition of human T-lymphotropic virus Type III/LAV(HIV) DNA synthesis and RNA expression in T cells protected by 2′,3′-dideoxynucleosides in vitro
296. 3′-azido-3′-deoxythymidine (BWA509U): An antiviral agent that inhibits the infecting and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy associated virus in vitro
297. Bone marrow toxicity of dideoxyinosine
298. Preclinical toxicology studies with acyclovir teratologic reproductive and neonatal tests
299. Zidovudine and the natural history of the acquired immunodeficiency syndrome
300. Successful combination therapy with acyclovir and vidarabine for disseminated varicella zoster virus infection with retinal involvement in a patient with B-cell lymphoma and adult T-cell leukemia
301. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy
302. Ocular histopathologic findings in a case of human herpes B virus infection
303. Simultaneous treatment of cytomegalovirus retinitis with ganciclovir and foscarnet
304. The treatment of Kawasaki syndrome with intravenous gamma globulin
305. Antiviral activity of ampligen against CMV in vitro [Abstract]
306. Properties of antiviral agents: First of two parts
307. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes
308. Antiviral effects of phosphonoformate (PFA foscarnet sodium)
309. Nucleoside metabolism in herpes simplex virus-infected cells following treatment with interferon and acyclovir a possible mechanism of synergistic antiviral activity
310. Enhancement of virus multiplication and interferon production by cortisone in ocular herpes virus infections
311. Combined short- and long-term therapy of cytomegalovirus retinitis using ganciclovir (BWB759U)
312. Decrease in the risk of bilateral acute retinal necrosis by acyclovir therapy
313. A randomized controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS
314. Ophthalmic involvement in acquired immune deficiency syndrome
315. Treatment of cytomegalovirus retinitis with dihydroxy propoxymethyl guanine
316. The management of ocular herpes
317. Clinical evaluation of adenine arabinoside and idoxuridine in treatment of routine and complicated herpes simplex keratitis
318. Major ocular viral infections
319. A double blind clinical study of adenine arabinoside therapy of viral keratoconjunctivitis
320. Herpetic ganglionic latency: Acyclovir and vidarabine therapy
321. Leukocyte interferon for treating first episodes of genital herpes in women
322. Antiviral sensitivities of the acute retinal necrosis syndrome virus
323. Concurrent herpes simplex and cytomegalovirus retinitis and encephalitis in the acquired immune deficiency syndrome (AIDS)
324. Acquired immune deficiency syndrome. Pathogenic mechanisms of ocular disease
325. Pathologic features of cytomegalovirus retinopathy after treatment with the antiviral agent ganciclovir
326. A randomized controlled trial of interferon alpha-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B
327. Acyclovir in herpes zoster
328. Vitrectomy and intravitreal antiviral drug therapy in acute retinal necrosis syndrome: Report of two cases
329. Intravitreal injection of liposome-encapsulated ganciclovir in a rabbit model
330. Epstein-Barr virus keratitis after a chemical facial peel
331. Nummular keratitis associated with infectious mononucleosis
332. Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl) guanine
333. In vitro and in vivo responses of cytomegalovirus to acyclovir
334. Intraocular anti-viral penetration
335. Cytomegalovirus retinitis in immunosuppressed hosts: I. Natural history and effects of treatment with adenine arabinoside
336. Infection of the retina by human immunodeficiency virus type I
337. A comparison of local and systemic acyclovir in the management of herpetic disciform keratitis
338. Toxicity of intravitreal antiviral drugs
339. Intravitreal toxicity of hydroxyacyclovir (BW-B759U) a new antiviral agent
340. Alpha interferon for induction of remission in hairy-cell leukemia
341. Clinical toxicity of interferons in cancer patients: a review
342. Herpesvirus infections in the acquired immune deficiency syndrome
343. Population-based study of herpes zoster and its sequelae
344. Inhibition of human cytomegalovirus replication by 9-(1,3-dihydroxy-2-propoxymethyl) guanine alone and in combination with human interferons
345. Infections associated with Hickman catheters in patients with acquired immunodeficiency syndrome
346. Continuous usage of low doses of human leukocyte interferon with contact lenses in herpetic keratoconjunctivitis
347. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants
348. Treatment of cytomegalovirus pneumonia with 9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine and high dose corticosteroids
349. Patient-initiated therapy of recurrent herpes simplex genitalis with orally administered acyclovir
350. Treatment of condyloma acuminatum with three different interferons administered intralesionally: A double-blind, placebo-controlled trial
351. Regression of oral hairy leukoplakia after orally administered acyclovir therapy
352. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial
353. Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infection in allograft recipients
354. A model of steroid effects in herpes keratitis
355. Use of human fibroblast-derived (beta) interferon in the treatment of epidemic adenovirus keratoconjunctivitis
356. Ten years experience with human fibroblast interferon in treatment of viral ophthalmic infections
357. Isolation of drug-resistant variants of HIV-1 from patients on longterm zidovudine therapy
358. Antiviral therapy with ganciclovir for cytomegalovirus retinitis and bilateral exudative retinal detachments in an immunocompromised child
359. Antiviral therapy for cytomegalovirus retinitis in AIDS with dihydroxy propoxymethyl guanine
360. Overview of Phase I trials of 2′, 3′,-dideoxyinosine (ddi) conducted on adult patients
361. Toxicity of adenine arabinoside in humans
362. Herpes simplex encephalitis in a patient with lymphoma: Relapse following acyclovir therapy
363. Granulocyte-macrophage colony stimulating factor: Pleiotropic cytokine with potential clinical usefulness
364. Clinical efficacy of adenine arabinoside on cytomegalovirus infections in renal allograft recipients
365. Antiviral treatment of chronic hepatitis B virus infection Pharmacokinetics and side effects of interferon and adenine arabinoside alone and in combination
366. Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: Preliminary data
367. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection
368. A controlled trial comparing foscarnet with vidarabine for acyclovirresistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome
369. 3′-azido-3′ deoxythymidine triphosphate as an inhibitor and substrate of purified HIV reverse transcriptase
370. Effectiveness of levamisole on stromal herpetic keratitis
371. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis: Use of an intravitreal device
372. Herpes zoster ophthalmicus in patients at risk for the acquired immunodeficiency syndrome (AIDS)
373. Inhibitor of human T-cell lymphotropic virus type III in vitro by phosphonoformate
374. Acyclovir in the treatment of herpetic stromal disease
375. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia
376. Acyclovir prophylaxis of herpes simplex virus infections: A randomized, double-blind, controlled trial in bone-marrow transplant recipients
377. Acyclovir chemistry and spectrum of activity
378. 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group
379. The effect of vidarabine on the development of the offspring of rats, rabbits, and monkeys
380. Treatment of cytomegalovirus associated pneumonitis with ganciclovir (DHPG) and immunoglobulin following allogeneic bone marrow transplantation: antiviral and therapeutic response
381. A randomized controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants
382. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex
383. Chronic Epstein-Barr virus infection associated with fever and interstitial pneumonitis: Clinical and serologic features and response to antiviral chemotherapy
384. Parenterally administered acyclovir for viral retinitis associated with AIDS
385. The intraocular penetration of acyclovir after subconjunctival administration
386. Intraocular 9-[hydroxy-1-(hydroxymethyl) ethoxy] guanine levels after intravitreal and subconjunctival administration
387. Oral acyclovir in the management of herpes simplex ocular infections
388. Use of intravenous acyclovir for treatment of herpes zoster ophthalmicus in patients at risk for AIDS
389. Suppression of cytomegalovirus retinitis in persons with AIDS with high-dose intravenous acyclovir
390. Ganciclovir hepatotoxicity
391. Activity of 9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine in the treatment of cytomegalovirus pneumonia
392. Treatment of varicella zoster virus infection in severely immunocom-promised patients: a randomized comparison of acyclovir and vidarabine
393. Oral acyclovir therapy for mucocutaneous herpes simplex infections in immunocompromised marrow transplant recipients
394. Acquired immunodeficiency syndrome (AIDS)
395. Foscarnet for cytomegalovirus retinitis [Letter]
396. Major depression with psychotic features associated with acyclovir therapy
397. Cytomegalovirus retinopathy as the initial manifestation of the acquired immunodeficiency syndrome
398. Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus
399. Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection
400. Acyclovir versus vidarabine in herpes simplex encephalitis: randomized multicenter study in consecutive Swedish patients
401. Dual infection of retina with human immunodeficiency virus type 1 and cytomegalovirus
402. Bidirectional interactions between human immunodeficiency virus type 1 and cytomegalovirus
403. Phase II trial of alternating and intermittent regimens of zidovudine (ZDV) and 2′,3′-dideoxycytidine (ddC) in ARC and AIDS [Abstract]
404. Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl) guanine
405. Lack of toxicity of a topical recombinant interferon alfa
406. Treatment of herpes simplex keratitis with levamisole
407. Use of cytomegalovirus immune globulins to prevent cytomegalovirus disease in renal transplant recipients
408. Cytomegalovirus immunoglobulins in the prevention and treatment of cytomegalovirus disease
409. Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function
410. Treatment of recurrent herpes simplex labialis with oral acyclovir
411. Human leukocyte interferon in the treatment and prophylaxis of acute hemorrhagic conjunctivitis
412. The effect of acetaminophen on zidovudine metabolism in HIV-infected patients
413. Varicella-zoster virus causes acute retinal necrosis [abstract]
414. Varicellazoster virus infections: Biology, natural history, treatment, and prevention
415. Oral acyclovir to suppress recurrent herpes simplex virus infections in immunodeficient patients
416. Suppression of frequently recurring genital herpes: A placebo-controlled double blind trial of oral acyclovir
417. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis
418. Orale Acyclovir-Therapie virologisch nachgewiesener intraokularer herpes simplex Virus Infektionen
419. Combination therapy for dendritic keratitis. High titre alpha-interferon and trifluridine
420. The potency of interferon-alpha 2 and interferon-gamma in a combination therapy of dendritic keratitis. A controlled clinical study
421. Zidovudine for the treatment of thrombocytopenia associated with HIV infection
422. Vesicular-eruption: a local complication of concentrated acyclovir infusions
423. Levamisole in the modulation of the immune response: The current experimental and clinical state
424. Synergistic antiherpes virus activity of acyclovir and interferon in human corneal stromal cells
425. Active cytomegalovirus particles in the eyes of an AIDS patient being treated with 9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine (ganciclovir)
426. Prevalence pathophysiology and treatment of rhegmatogenous retinal detachment in treated cytomegalovirus retinitis (Letter)
427. Effects of the nucleoside analog 2′-nor-2′-deoxyguanosine on human cytomegalovirus replication
428. Psychiatric side-effects of acyclovir in patients with chronic renal failure
429. Effect of acyclovir on acute and latent herpes simplex virus infections in the rabbit
430. Preclinical toxicology studies with acyclovir carcinogenicity bioassays and chronic toxicity tests
431. BWB759U an analogue of acyclovir, inhibits human cytomegalovirus in vitro
432. Disseminated herpes simplex infection with retinitis in a renal allograft recipient
433. Intravitreal ganciclovir in the treatment of AIDS associated with cytomegalovirus retinitis
434. The use of foscarnet in the treatment of AIDS-associated cytomegalovirus retinitis [abstract]
435. Lack of effect of peroral acyclovir for the treatment of infectious mononucleosis
436. Pharmacokinetics of orally administered acyclovir in patients with herpes progenitalis
437. Fatal vidarabine toxicity in a patient with normal renal function
438. Acyclovir treatment in stromal herpetic keratitis
439. Relapse of herpes simplex encephalitis after conventional acyclovir therapy
440. Foscarnet and penile ulceration
441. Toxicity of intravitreal interferon-beta
442. Evolution of the therapy for cytomegalovirus infection
443. Zidovudine in asymptomatic human immunodeficiency virus infection: A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter
444. Treatment of cytomegalovirus pneumonia with high dose acyclovir
445. Neurologic symptoms associated with parenteral acyclovir treatment after bone marrow transplantation
446. Intravenous acyclovir to treat mucocutaneous herpes simplex infection after marrow transplantation
447. Reversible inhibition of cytomegalovirus replication by phosphonoformate
448. Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (Foscarnet)
449. Interferons in the treatment of human papillomavirus diseases
450. Long-term outpatient treatment of CMV retinitis with ganciclovir in AIDS patients
451. Clinical evaluation of trifluorothymidine in the treatment of herpes simplex corneal ulcers
452. Antiviral effects of interferon in different virus-host cell systems
453. Retinal toxicity in human immunodeficiency virus-infected children treated with 2′,3′-dideoxyinosine
454. The frustrations of treating herpes simplex virus infections of the central nervous system
455. Vidarabine: A preliminary review of its pharmacological properties and therapeutic use
456. Vidarabine versus acyclovir therapy in herpes simplex encephalitis
457. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection
458. Pharmacokinetics of acyclovir in humans following intravenous administration: a model for the development of parenteral antivirals
459. Vidarabine therapy of varicella in immunosuppressed patients
460. Adenine arabinoside therapy of biopsy-proven herpes simplex encephalitis
461. Early vidarabine therapy to control the complications of herpes zoster in immunosuppressed patients
462. Ocular involvement in infectious mononucleosis
463. Diagnosis and management of herpes simplex stromal keratitis
464. Recombinant interferon alfa for the treatment of herpes zoster in immunosuppressed patients with cancer
465. Intravenous immune globulin for prevention of cytomegalovirus and interstitial pneumonia after bone marrow transplantations
466. Cytomegalovirus immune plasma in bone marrow transplant recipients
467. Ocular involvement associated with chronic Epstein-Barr virus disease
468. Efficacy of oral acyclovir treatment of acute herpes zoster
469. Administration of 3′-azido-3″ deoxythymidine, an inhibitor of HTLV-III replication to patients with AIDS and AIDS-related complex
470. Clinical pharmacology of 3′-azido-2,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides
471. Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT)
472. Long-term toxicity/activity profile of 2′3′-dideoxyinosine in AIDS or AIDS-related complex
473. Long-term administration of 3′-azido-2′3′-dideoxythymidine to patients with AIDS-related neurological disease
474. Acute retinal necrosis syndrome following herpes zoster dermatitis
475. Ocular toxicity of multiple intravitreal DHPG injections
476. Acyclovir-resistant herpes in AIDS treated with foscarnet
477. Severe hypocalcemia in AIDS patients treated with foscarnet and pentamidine
478. Inhibition of human renal epithelial sodium phosphate co-transport by phosphonoformic acid